AYA   

Bleomycin omitted due to asymptomatic decline in DLCO

What would you want community oncologists to know when following these patients? Are there any other special issues to follow especially in AYA?

For patients not on study, would you consider replacing missed doses of peg with a non-asparaginase based chemotherapy?

How is your approach different from or similar to those who undergo surgical menopause? 

If serum markers were normal, how strongly do you consider 1 cycle of BEP for embryonal predominant pathology? 

VIP can be considered, but given complex psychosocial issues and limited community cancer treatment resources, this question is being asked. 

NCCN guidelines state check at baseline and then as clinically indicated. Some other sources state, can check prior to each cycle of BEP?  What ...

Given persistent embryonal histology on RPLND, do you favor observation or TIP/VIP? What do you use to guide your decision?

How does your treatment approach vary depending on the underlying predisposition?

Do your recommendations differ between those who receive ABVD and escalated BEACOPP? Do you recommend consultation with fertility specialists for all...

While this is a known risk factor for venous [Meijers et al NEJM 2000] and potentially arterial [Yang et al, Am J Clin Pathol 2006] thrombosis, it is ...

In follow up to @Jacqueline Casillas presentation at ASCO 2021 regarding models of survivorship care delivery for AYA patients. 

NCCN guideline V4.2021 DLBCL page BCEL-3 states stage I-II, bulky >= 7.5cm should be treated with 6 cycles of RCHOP, but most bone lymphoma studies...

Since desmoid tumors are associated with high estrogen states, is there an optimal contraception approach? Is there an optimal time for pregnancy? How...

After optimizing symptoms and reversible factors, and attempting cognitive-behavioral interventions and exercise, do you recommend pharmacologic agent...

Presented with mass projecting into right/left anterior ethmoid complex

Would you consider “bridging” therapy with something like an HMA?

Does acute leukemia sub-type affect your decision? 

What are there most evidence-based options?

At what age would you treat an early stage hodgkins lymphoma patient with ABVD + RT (adult treatment) vs OEPA x 2 or AV-PC x 3 (pediatric paradigm)?&n...

Do you limit it to post-pubertal patients? Do you offer it only if they will proceed with bone marrow transplantation after CAR-T?

GI work up negative. NGS cancer type and isochromosome 12p ordered and pending. Pathology at RPLND was negative for cancer.  

-The data on induction for adult H&N ca has been mixed (excluded NPX) but recent data suggest a benefit for adult NPX. -Given that this is standa...

Do you reserve this approach for only women with triple negative breast cancer or all-comers?